MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Adamas Pharmaceuticals (ADMS)
Organization & Developments: Adamas
Parents
Adamas Pharmaceuticals (ADMS)
Children
2014: Developing its portfolio of central nervous system drugs, including those targeted at Alzheimer's disease-related dementia, Parkinson's disease and traumatic brain injury
2014: The company has a deal with Forest Laboratories Inc. (NYSE: FRX) around the dementia drug MDX-8704.
2017: Adamas Pharmaceuticals: Still Upside After Big Rally - Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
2017: FDA OKs Adamas Pharma's amantadine for Parkinson's disease (PD)-related dyskinesia; shares up 35% after hours - Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
2017: Should You Buy Adamas Pharmaceuticals Stock Ahead Of Upcoming PDUFA On August 24? - Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
2018: Adamas Gets Beat Down For Beating Q3 Estimates - Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
2018: Adamas Sell-Off: An Overreaction And A Buying Opportunity
2018: Adamas: A Look At The Potential Opportunity With Gocovri In LID - Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
2018: Adamas: Not A One-Trick Pony_seekingalpha.com
2019: Adamas: INROADS Data Sell-Off Goes Too Far_seekingalpha.com
2019: Recent Adamas Report Provides Projections And Trends To Profitability - Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
2020: Adamas Pharmaceuticals: Feeling Bullish After Impressive Growth In Q2
2020: Adamas Pharmaceuticals: Unjustified Sell-Off Following Another Strong Quarter
Jumps
*Key People: Adamas
Finance & Acquisitions: Adamas